Authors’ relationships and activities
Nordisk, Diabetes
MAY, DIABETES
CL was employed by Steno Diabetes Center Copenhagen during the conduct of the study, but as of 1 November 2022 is employed by, and owns shares in, Novo Nordisk. SS has received fees for speaking from Novo Nordisk and as of 1 May 2022 is employed by Novo Nordisk. KN serves as an adviser to Medtronic, Abbott, Convatec and Novo Nordisk; owns shares in Novo Nordisk; has received research grants to the institution from Novo Nordisk, Zealand Pharma, Dexcom and Medtronic; and has received fees for speaking from Medtronic, Novo Nordisk and Dexcom. The authors declare that there are no other relationships or activities that might bias, or be perceived to bias, their work.